Article
Infectious Diseases
Marianna Meschiari, Alessandro Cozzi-Lepri, Adriana Cervo, Guido Granata, Carlotta Rogati, Erica Franceschini, Stefania Casolari, Paola Tatarelli, Daniele Roberto Giacobbe, Matteo Bassetti, Simone Mornese Pinna, Francesco Giuseppe De Rosa, Francesco Barchiesi, Benedetta Canovari, Carolina Lorusso, Giuseppe Russo, Giovanni Cenderello, Antonio Cascio, Nicola Petrosillo, Cristina Mussini
Summary: This study aimed to evaluate the efficacy of Bezlotoxumab (BEZ) in preventing the recurrence of Clostridioides difficile infection (rCDI) in a real-world setting. The results showed that adding BEZ to standard of care (SoC) treatment reduced the occurrence of rCDI within 30 days compared to SoC alone in high-risk patients.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2023)
Review
Medicine, General & Internal
Ibrahim A. Al-Zahrani
Summary: Clostridioides difficile (C. difficile) infection is a global threat to many healthcare settings. Excessive use of antimicrobials, lack of optimal antibiotic policies, and suboptimal infection control practices have fueled the development of this health issue. Prudent use of antimicrobials and simple infection control measures can significantly reduce infection rates.
SAUDI MEDICAL JOURNAL
(2023)
Article
Gastroenterology & Hepatology
Steven J. Mileto, Melanie L. Hutton, Sarah L. Walton, Antariksh Das, Lisa J. Ioannidis, Don Ketagoda, Kylie M. Quinn, Kate M. Denton, Diana S. Hansen, Dena Lyras
Summary: This study investigated the systemic complications of C. difficile infection using a mouse model, focusing on thymic damage and serum markers. The efficacy of bezlotoxumab in preventing systemic disease complications was also examined. The study found that C. difficile infection causes thymic damage, depletion of thymocytes, and changes in liver and kidney function markers. Administration of bezlotoxumab prevented systemic disease and thymic atrophy without blocking gut damage.
Review
Infectious Diseases
Guido Granata, Francesco Schiavone, Giuseppe Pipitone
Summary: Bezlotoxumab administration during a first CDI episode is effective and safe in reducing the rate of rCDI. Despite its high cost, evidence suggests considering bezlotoxumab in patients with a primary CDI episode. Further studies are needed to assess the benefit in specific subgroups of primary CDI patients and to define the risk factors to guide bezlotoxumab use.
Article
Infectious Diseases
Alice Annalisa Medaglia, Alessandro Mancuso, Chiara Albano, Giuseppe Zinna, Luca Pipito, Cinzia Cala, Rita Immordino, Raffaella Rubino, Silvia Bonura, Baldassare Canino, Giuseppe Calamusa, Claudia Colomba, Pier Luigi Almasio, Antonio Cascio
Summary: Clostridioides difficile infection (CDI) is a significant cause of morbidity and mortality, especially in frail patients. This study aimed to determine the incidence of CDI and identify risk factors for mortality and recurrence. The findings showed a significant increase in CDI incidence over the past decade and identified hemodialysis as a significant risk factor for mortality.
Article
Immunology
Stuart Johnson, Diane M. Citron, Dale N. Gerding, Mark H. Wilcox, Ellie J. C. Goldstein, Susan P. Sambol, Emma L. Best, Karen Eves, Erin Jensen, Mary Beth Dorr
Summary: In the MODIFY I/II trials, infection with BI strains of C. difficile was associated with poor outcomes. Bezlotoxumab treatment was effective in both BI and non-BI subpopulations.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Microbiology
Jennifer J. Dawkins, Jessica R. Allegretti, Travis E. Gibson, Emma McClure, Mary Delaney, Lynn Bry, Georg K. Gerber
Summary: This study conducted a longitudinal analysis of the gut microbiome and metabolome changes in patients with primary Clostridioides difficile infection (CDI). The results showed that metabolomic data can accurately predict the recurrence of CDI, providing important insights for the development of diagnostic tests and treatments.
Article
Plant Sciences
Young-Jin Son, Young-Rok Kim, Sang-Hun Oh, Sungji Jung, Marco A. Ciufolini, Hee-Jong Hwang, Jin-Hwan Kwak, Hyunjoo Pai
Summary: Clostridioides difficile infection is a global health threat and micrococcin P2 (MP2) has shown promising results as an effective antimicrobial agent against the hypervirulent C. difficile strain through in vitro and in vivo studies.
JOURNAL OF NATURAL PRODUCTS
(2022)
Article
Infectious Diseases
Jiahe Chen, Cynthia L. Gong, Matthew M. Hitchcock, Marisa Holubar, Stanley Deresinski, Joel W. Hay
Summary: The study evaluated the cost-effectiveness of fidaxomicin and bezlotoxumab in treating initial CDI compared to standard therapy with oral vancomycin. Extended-pulsed fidaxomicin was found to be the most cost-effective treatment, while standard fidaxomicin was more effective than vancomycin and the bezlotoxumab-containing regimen required higher costs.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Biochemistry & Molecular Biology
Kun Karnchanapandh, Chonnikan Hanpaibool, Kamonpan Sanachai, Thanyada Rungrotmongkol
Summary: C. difficile infection is a major global epidemic, and this study compared the interaction of the antibody Bez with toxins B1 and B2 using molecular dynamics simulations and binding free energy calculations. The results showed that Bez binds more strongly to B1 compared to B2, primarily due to differences in their interaction modes.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Review
Microbiology
Joshua Heuler, Louis-Charles Fortier, Xingmin Sun
Summary: Clostridioides difficile, formerly known as Clostridium difficile, is the causative agent of C. difficile infections, which pose challenges in healthcare settings. Antibiotic-induced dysbiosis allows C. difficile colonization in the gut. Phage infection offers potential new treatment strategies against C. difficile infections.
FEMS MICROBIOLOGY REVIEWS
(2021)
Review
Microbiology
Joshua Heuler, Louis-Charles Fortier, Xingmin Sun
Summary: Clostridioides difficile, previously known as Clostridium difficile, is the causative agent of CDI. Antibiotics-induced dysbiosis of the microbiota is the primary factor allowing C. difficile to colonize the gut and cause diseases. Phages infecting C. difficile could offer new treatment strategies and insights into its biology.
FEMS MICROBIOLOGY REVIEWS
(2021)
Article
Infectious Diseases
Thomas J. Sferra, Tomas Merta, Michael Neely, Claudia Murta de Oliveira, Alvaro Lassaletta, Claudia Fortuny Guasch, Mary Beth Dorr, Gregory Winchell, Feng-Hsiu Su, Sarah Perko, Doreen Fernsler, Hetty Waskin, Stephen R. Holden
Summary: This study evaluated the pharmacokinetics, safety, tolerability, and efficacy of bezlotoxumab in pediatric patients, and concluded that the dose of 10 mg/kg is effective for children.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY
(2023)
Article
Medicine, General & Internal
Sahil Khanna
Summary: Clostridioides difficile infection is the most common cause of infectious diarrhea in hospitals with increasing incidence in the community. Management includes diagnostics, newer antibiotics, antibody treatments, and microbiome restoration therapies.
MAYO CLINIC PROCEEDINGS
(2021)
Review
Gastroenterology & Hepatology
Shintaro Akiyama, Akihiro Yamada, Yuga Komaki, Fukiko Komaki, Dejan Micic, Atsushi Sakuraba
Summary: The meta-analysis demonstrated the efficacy and safety of bezlotoxumab for preventing rCDI, particularly in high-risk patients. Additionally, there were no significant differences in safety outcomes between bezlotoxumab-treated patients and those who received a placebo.
JOURNAL OF CLINICAL GASTROENTEROLOGY
(2021)
Article
Immunology
Carlos Mejia-Chew, Peggy L. Carver, Sasinuch Rutjanawech, Luis F. Aranha Camargo, Ruan Fernandes, Sara Belga, Shay Anne Daniels, Nicolas J. Mueller, Sara Burkhard, Nicole M. Theodoropoulos, Douwe F. Postma, Pleun J. van Duijn, Maria Carmen Farinas, Claudia Gonzalez-Rico, Jonathan Hand, Adam Lowe, Marta Bodro, Elisa Vanino, Ana Fernandez Cruz, Antonio Ramos, Mateja Jankovic Makek, Ribal Bou Mjahed, Oriol Manuel, Nassim Kamar, Antonia Calvo-Cano, Laura Rueda Carrasco, Patricia Munoz, Sara Rodriguez, Sandra Perez-Recio, Nuria Sabe, Regino Rodriguez Alvarez, Jose Tiago Silva, Alessandra Mularoni, Elisa Vidal, Juana Alonso-Titos, Teresa del Rosal, Annika Y. Classen, Charles W. Goss, Mansi Agarwal, Francisco Lopez-Medrano
Summary: This study aimed to describe the risk factors for nontuberculous mycobacteria (NTM) infections after solid organ transplant (SOT). The results showed that older age, prior hospital admission, receipt of antifungals, and lymphocyte-specific antibodies were associated with NTM infection.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Immunology
Rocio Montejano, Fernando de la Calle-Prieto, Maria Velasco, Carlos Guijarro, Javier Queiruga-Parada, Maria Jimenez-Gonzalez, Patricia Gonzalez-Ruano, Patricia Martinez, Ane Josune Goikoetxea, Marta Ibarrola, Marianela Ciudad, Angela Gutierrez, Miguel Torralba, Ana Diaz-Brasero, Pablo Ryan, Cristina Marcelo, Cristina Diez, Sofia Ibarra, Esperanza Merino, Vicente Estrada, Javier Marcos, Maria Novella, Maria A. Rivera, Manuel Ruiz-Munoz, Marta de Miguel, Llanos Soler, Mikel Del Alamo, Santiago Moreno, Antonio J. Carcas, Alberto M. Borobia, Jose R. Arribas
Summary: This study aimed to evaluate the effectiveness of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) treatment in high-risk patients with severe COVID-19. The results showed that TDF/FTC did not provide significant benefits, while the beneficial effect of baricitinib, as established by prior clinical trials, was confirmed.
CLINICAL INFECTIOUS DISEASES
(2023)
Editorial Material
Immunology
Jesus Rodriguez-Bano, Belen Gutierrez-Gutierrez
CLINICAL INFECTIOUS DISEASES
(2023)
Letter
Infectious Diseases
Elena Munez-Rubio, Jorge Calderon-Parra, Ana Fernandez-Cruz, Victor Moreno-Torres, Silvia Blanco-Alonso, Antonio Ramos-Martinez
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Surgery
Elena Perez-Nadales, Mario Fernandez-Ruiz, Alejandra M. Natera, Belen Gutierrez-Gutierrez, Alessandra Mularoni, Giovanna Russelli, Ligia Camera Pierrotti, Maristela Pinheiro Freire, Marco Falcone, Giusy Tiseo, Mario Tumbarello, Francesca Raffaelli, Edson Abdala, Marta Bodro, Elena Gervasi, Maria Carmen Farinas, Elena M. Seminari, Juan Jose Caston, Juan Antonio Marin-Sanz, Victor Galvez-Soto, Meenakshi M. Rana, Belen Loeches, Pilar Martin-Davila, Alvaro Pascual, Jesus Rodriguez-Bano, Jose Maria Aguado, Luis Martinez-Martinez, Julian Torre-Cisneros, REIPI INCREMENT-SOT Study Grp
Summary: This study compared the efficacy of ceftazidime-avibactam (CAZ-AVI) and the best available therapy (BAT) in treating solid organ transplant recipients with bloodstream infection caused by carbapenemase-producing Klebsiella pneumoniae. The results showed that patients treated with CAZ-AVI had higher clinical success rates at 14-day and 30-day and lower 30-day mortality compared to those receiving BAT.
AMERICAN JOURNAL OF TRANSPLANTATION
(2023)
Article
Infectious Diseases
Itziar Diego-Yague, Alberto Mora-Vargas, Jose Manuel Vazquez-Comendador, Beatriz Santamarina-Alcantud, Ana Fernandez-Cruz, Elena Munez-Rubio, Andrea Gutierrez-Villanueva, Isabel Sanchez-Romero, Victor Moreno-Torres, Antonio Ramos-Martinez, Jorge Calderon-Parra
Summary: Oral sequential therapy (OST) in uncomplicated Staphylococcus aureus bacteraemia (SAB) is found to be safe and effective, reducing mortality and microbiological failure.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Infectious Diseases
Rosa Escudero-Sanchez, Elena Rubio Martin, Pilar Vizcarra, Francisco Braojos Sanchez, Alvaro Diaz Gago, Laura Del Campo Albendea, Alfonso Muriel, Ana Halperin, Manuel Ponce Alonso, Santiago Moreno Guillen, Javier Cobo
Summary: In this study, the recurrence rate of Clostridioides difficile infection (CDI) was compared between conventional dosing of fidaxomicin (FCD) and extended-pulsed dosing of fidaxomicin (FEPD). The results showed no significant difference in the recurrence rate between the two dosing regimens. Further clinical trials or large observational studies are needed to compare the efficacy of these two dosing regimens.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Dermatology
Natalia Vicente Lopez, Jorge Calderon Parra, Alejandro Munoz Serrano, Andrea Gutierrez Villanueva, Sara de la Fuente Moral, Victor Moreno-Torres, Elena Munez Rubio, Antonio Ramos Martinez
Summary: This study evaluated the adherence to clinical management recommendations for candidemia in elderly patients, and found an improvement in adherence after specific training. In the second period, there was better compliance in various aspects including echocardiogram performance, fundoscopy, follow-up blood cultures, removal of central venous catheter, and adequate antifungal treatment. The real impact of this intervention on mortality needs to be evaluated with a larger sample size.
Article
Medicine, General & Internal
Salvador Perez-Galera, Jose M. Bravo-Ferrer, Maria Paniagua, Tomislav Kostyanev, Marlieke E. A. de Kraker, Jan Feifel, Jesus Sojo-Dorado, Joost Schotsman, Rafael Canton, George L. Daikos, Biljana Carevic, Gorana Dragovac, Lionel K. Tan, Lul Raka, Adriana Hristea, Pierluigi Viale, Murat Akova, Jose Maria Reguera, Lucia Valiente de Santis, Julian Torre-Cisneros, Angela Cano, Emmanuel Roilides, Lili Radulovic, Cenk Kirakli, Evelyn Shaw, Matthew E. Falagas, Vicente Pintado, Herman Goossens, Marc J. Bonten, Belen Gutierrez-Gutierrez, Jesus Rodroguez-Bano
Summary: A study found that the main risk factors for CRE infections in hospitals with high incidence included previous colonization, urinary catheter use, and exposure to broad spectrum antibiotics.
Article
Infectious Diseases
Laura Corbella, Mario Fernandez-Ruiz, Maria Ruiz-Ruigomez, Isabel Rodriguez-Goncer, Jose Tiago Silva, Pilar Hernandez-Jimenez, Francisco Lopez-Medrano, Manuel Lizasoain, Jennifer Villa, Jose Maria Aguado, Rafael San-Juan
Summary: The production of OXA-48 carbapenemase is independently associated with poor outcomes in Klebsiella pneumoniae infection. The study found lower clinical cure rates and higher 30-day all-cause mortality in OXA-48-Kp cases compared to non-OXA-48-Kp cases. Multivariate analysis confirmed the independent association between OXA-48-Kp infection and the lack of 14-day clinical cure.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
Victor Moreno-Torres, Maria Martinez-Urbistondo, Jorge Calderon-Parra, Patricia Mills, Alejandro Munoz-Serrano, Ana Arias-Milla, Laura Benitez, Myriam Aguilar-Perez, Elena Munez-Rubio, Antonio Ramos-Martinez, Ana Fernandez-Cruz, Valentin Cuervas-Mons, Carmen de Mendoza
Summary: This study evaluated the mortality of solid organ transplant recipients hospitalized with COVID-19 in Spain and found that lung transplant recipients had a higher mortality rate. Lung transplantation was the strongest prognostic factor in SOT patients. Efforts should be focused on the optimal management of lung transplant recipients with COVID-19.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Public, Environmental & Occupational Health
Alfredo Maldonado-Barrueco, Cristina Utrilla, Ana Hernandez-Gonzalez, Maria J. Perteguer, Beatriz Diaz-Pollan, Yeray Untoria-Tabares, Marta Diaz-Menendez, Iker Falces-Romero, Almudena Gutierrez-Arroyo, Julio Garcia-Rodriguez, Dolores Montero-Vega
Summary: We present a confirmed case of intraventricular neurocysticercosis in a migrant from Choluteca, Honduras, in Madrid, Spain, based on epidemiological, radiological, and microbiological criteria.
JOURNAL OF TRAVEL MEDICINE
(2023)
Article
Multidisciplinary Sciences
Antonio Ramos-Martinez, Fernando Dominguez, Patricia Munoz, Mercedes Marin, Alvaro Pedraz, M. Carmen Farinas, Valentin Tascon, Aristides de Alarcon, Raquel Rodriguez-Garcia, Jose Maria Miro, Josune Goikoetxea, Guillermo Ojeda-Burgos, Francesc Escrihuela-Vidal, Jorge Calderon-Parra
Summary: Prosthetic valve endocarditis (PVE) is a serious infection that often requires surgical treatment. The study found that patients with early-onset PVE were more likely to have complications compared to patients with late-onset PVE. The overall in-hospital mortality of PVE was 32.6%, and patients who did not undergo surgery had a higher mortality rate compared to those who had surgery.
Article
Critical Care Medicine
Marius Troseid, Jose R. Arribas, Lambert Assoumou, Aleksander Rygh Holten, Julien Poissy, Vida Terzic, Fulvia Mazzaferri, Jesus Rodriguez Bano, Joe Eustace, Maya Hites, Michael Joannidis, Jose-Artur Paiva, Jean Reuter, Isabel Puentmann, Thale D. J. H. Patrick-Brown, Elin Westerheim, Katerina Nezvalova-Henriksen, Lydie Beniguel, Tuva Borresdatter Dahl, Maude Bouscambert, Monika Halanova, Zoltan Peterfi, Sotirios Tsiodras, Michael Rezek, Matthias Briel, Serhat Unal, Martin Schlegel, Florence Ader, Karine Lacombe, Cecilie Delphin Amdal, Serge Rodrigues, Kristian Tonby, Alexandre Gaudet, Lars Heggelund, Joy Mootien, Asgeir Johannessen, Jannicke Horjen Moller, Beatriz Diaz Pollan, Anders Aune Tveita, Anders Benjamin Kildal, Jean-Christophe Richard, Olav Dalgard, Victoria Charlotte Simensen, Aliou Balde, Lucie de Gastines, Marta del Alamo, Burc Aydin, Fridtjof Lund-Johansen, Mary-Anne Trabaud, Alpha Diallo, Bente Halvorsen, John-Arne Rottingen, Evelina Tacconelli, Yazdan Yazdanpanah, Inge C. Olsen, Dominique Costagliola
Summary: The study conducted a placebo-controlled trial of baricitinib in severe/critical COVID cases. The results showed that baricitinib did not reduce mortality within 60 days, and there may be safety risks in vaccinated participants, which require further investigation.
Article
Infectious Diseases
Mario Agreda Fernandez, Julia Origuen, Isabel Rodriguez-Goncer, Rafael San Juan, Francisco Lopez-Medrano, Patricia Parra, Tamara Ruiz-Merlo, Natalia Redondo, Maria Angeles Orellana, Jose Maria Aguado, Mario Fernandez-Ruiz
Summary: Measuring fecal calprotectin (FC) and lactoferrin (FL) levels in patients with Clostridioides difficile infection (CDI) can predict recurrence and severity of the disease. By modifying the thresholds for assay positivity, these biomarkers can be used to individualize CDI management.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2023)
